While the medication itself is not recognised as a direct cause, certain health conditions, lifestyle factors, and treatment-related changes may increase susceptibility during weight loss
The beyond-use date indicated on the Tirzepatide ODT packaging represents the date beyond which the medication should not be used, as established by stability testing under specified storage conditions
While blood clots are not a recognized side effect of GLP-1 medications, patients should remain aware of warning signs, particularly given that obesity itself increases thrombotic risk
I do not advise and understand the drive to find someone who can and will treat successfully
In clinical trials, patients taking this treatment achieved an average weight loss of 15-22% body weight of their body weight
Patent timelines and rules can vary by country, and in some cases, lower-cost versions of similar drugs have shown up earlier in places like India or China once local patents expire or get challenged